Indian multinational pharmaceutical company producing generics, APIs, biosimilars, and consumer health products across more than 30 countries.
drreddys.comLegal name
Dr. Reddy's Laboratories LimitedFounded
1984 (incorporated 24 February 1984)
Headquarters
Hyderabad, Telangana, India
Industry
Pharmaceuticals
Employees
24,832 (as of March 2023)
Revenue (FY25)
Rs 33,741 crore (approx US$3.9 billion)
Market Cap
Rs 98,680 crore (approx US$11.5 billion)
Listed on
NSE: DRREDDY, BSE: 500124, NYSE: RDY
CEO
Erez Israeli
Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Founded by Kallam Anji Reddy in 1984 and incorporated on 24 February 1984, it operates under the corporate identity number L85195TG1984PLC004507. The company is listed on the National Stock Exchange (DRREDDY), the Bombay Stock Exchange (500124), and the New York Stock Exchange (RDY), and is a constituent of the NIFTY 50 index.
The company's businesses span generics, active pharmaceutical ingredients (API) and services, innovative medicines, and consumer health. It develops and markets branded and unbranded generics, biosimilars, over-the-counter products, and APIs across more than 30 countries, with major markets in India, the United States, Europe, and emerging markets. Its U.S. headquarters is located in East Brunswick, New Jersey.
For fiscal year 2025, Dr. Reddy's reported revenue of about Rs 33,741 crore. The company employed roughly 24,832 people as of March 2023. Its leadership includes Chairman K. Satish Reddy, Co-Chairman and Managing Director G. V. Prasad, Chief Executive Officer Erez Israeli, and Chief Financial Officer M. V. Narasimham, who was elevated to the role on 1 August 2024.
Co-Chairman & Managing Director
Chief Executive Officer
Chairman
Chief Financial Officer
Interview experience
7/10
Interview difficulty
Medium
Interview process length
About a week
Practice real interview questions and get instant, structured feedback.
Q: Do you have Excel knowledge and sales knowledge or not?
A: Be direct about your actual comfort level, then back it with a concrete example. If you know Excel, name the functions you use and tie sales knowledge to a target you hit.
Q: Why do you want to associate with us?
A: Connect your motivation to something specific about Dr Reddy's: its therapy areas, market reach, or values. Then show how the role fits your career path.
Q: What are your career options after 4 years and what are your future plans?
A: Show a realistic path that stays within the sales or field-management track. Frame growth in terms of scope and impact, not just titles.
Q: Give three points on why we should hire you.
A: Pick three distinct strengths, one per point, and pin each to evidence. Aim for a mix of results, leadership, and domain fit.
Practice real interview questions and get instant, structured feedback.
Average
₹17,61,141/year
12 salaries Salaries submitted
Average
₹15,43,733/year
7 salaries Salaries submitted
Average
₹13,54,193/year
9 salaries Salaries submitted
Average
₹13,42,572/year
9 salaries Salaries submitted
Average
₹13,21,290/year
4 salaries Salaries submitted
Average
₹12,34,148/year
3 salaries Salaries submitted
Benchmark your pay against real reported salaries and negotiate with confidence.
Hyderabad, Telangana, India • Full-time
Hyderabad, Telangana, India • Full-time
Hyderabad, Telangana, India • Full-time
Hyderabad, Telangana, India • Full-time
Hyderabad, Telangana, India • Full-time
Hyderabad, Telangana, India • Full-time
Tailor your resume to each role and beat the applicant tracking system.
July 22, 2026
Dr Reddy's Q1 FY27 profit falls 69% to Rs 443.5 crore
Dr Reddy's reported consolidated net profit down 69% to Rs 443.5 crore for the quarter ended June 2026, with revenue down 6% to Rs 8,070.5 crore. The company cited a Rs 239.7 crore semaglutide API inventory provision and a 35% drop in North America revenue.
#earnings #Q1FY27 #pharma
View postJune 27, 2026
USFDA issues Form 483 with seven observations for Bachupally biologics plant
After a pre-license inspection held June 16 to 25, 2026, the USFDA issued a Form 483 with seven observations at Dr Reddy's biologics manufacturing facility in Bachupally, Hyderabad. The company said it will address the findings within the prescribed timeline.
#USFDA #regulatory #manufacturing
View postMay 20, 2026
Dr Reddy's launches oral semaglutide tablets at Rs 99 per pill
Dr Reddy's introduced oral semaglutide in India after CDSCO approval, priced at Rs 99 for the 3 mg tablet, Rs 135 for 7 mg and Rs 225 for 14 mg. Clinical trials on 288 patients showed non-inferior efficacy to the innovator drug.
#GLP1 #diabetes #productlaunch
View postMay 20, 2026
Dr Reddy's builds GLP-1 portfolio spanning India and Canada
Dr Reddy's said it is building a comprehensive GLP-1 portfolio with in-house development for supply stability, following its earlier launch of injectable semaglutide in India and Canada.
#GLP1 #strategy #diabetes
View postFebruary 26, 2026
Dr Reddy's gears up for March launch of generic injectable semaglutide Obeda
Dr Reddy's prepared to launch its generic injectable semaglutide under the brand Obeda in India in March 2026, following expiry of the innovator's patent. The pre-filled pen entered the fast-growing injectable antidiabetic and anti-obesity segment.
#Obeda #semaglutide #patentexpiry
View postDr Reddy's is an Indian multinational pharmaceutical company. It makes generics, active pharmaceutical ingredients, biosimilars, innovative medicines, and consumer health products, selling across more than 30 countries.
